drugset / Trial / NCT04992247
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2a randomized, placebo-controlled study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 "long haul" pulmonary compromise.
Timeline
- Start
- 2024-02
- Primary completion
- 2024-07
- Completion
- 2024-09
Outcome
Outcome not reported
Stopped: “Sorrento Therapeutics filed for chapter 11 bankruptcy.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COVI-MSC | Cell therapy | 3e+07 cells | Intravenous |
| Subject | COVI-MSC | Cell therapy | 6e+07 cells | Intravenous |
| Subject | COVI-MSC | Cell therapy | 9e+07 cells | Intravenous |